Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ARGX – argenx SE

argenx SE
ARGX
$560.14
Name : argenx SE
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $34,201,925,632.00
EPSttm : 16.41
finviz dynamic chart for ARGX
argenx SE
$560.14
0.02%
$0.1

Float Short %

3.32

Margin Of Safety %

Put/Call OI Ratio

0.6

EPS Next Q Diff

0.48

EPS Last/This Y

EPS This/Next Y

7.8

Price

559.66

Target Price

753.45

Analyst Recom

1.3

Performance Q

-5.62

Relative Volume

1.17

Beta

0.38

Ticker: ARGX




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02ARGX584.710.650.297453
2025-06-03ARGX576.840.650.027458
2025-06-04ARGX573.050.600.157865
2025-06-05ARGX580.310.520.038688
2025-06-06ARGX585.880.480.689144
2025-06-09ARGX583.370.481.039180
2025-06-10ARGX574.860.481.219215
2025-06-11ARGX575.190.481.589253
2025-06-12ARGX585.990.481.459286
2025-06-13ARGX577.340.481.259341
2025-06-16ARGX5510.480.409348
2025-06-17ARGX540.260.460.969930
2025-06-18ARGX537.770.441.099982
2025-06-20ARGX542.590.450.9610084
2025-06-23ARGX540.350.370.996093
2025-06-24ARGX568.130.413.436422
2025-06-25ARGX560.390.463.276670
2025-06-26ARGX559.870.512.947001
2025-06-27ARGX559.770.600.187402
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02ARGX584.59535.9-62.712.08
2025-06-03ARGX576.61535.9-54.212.08
2025-06-04ARGX574.03535.9-58.312.08
2025-06-05ARGX580.59535.9-53.312.08
2025-06-06ARGX585.28535.9-52.612.08
2025-06-09ARGX583.62535.9-57.412.08
2025-06-10ARGX575.41535.9-60.312.08
2025-06-11ARGX575.38535.9-57.012.08
2025-06-12ARGX586.76535.9-47.812.08
2025-06-13ARGX577.36535.9-53.712.08
2025-06-16ARGX551.30532.2-67.812.01
2025-06-17ARGX540.38532.2-61.612.01
2025-06-18ARGX537.92532.2-56.612.01
2025-06-20ARGX542.15532.0-53.912.00
2025-06-23ARGX540.38532.0-54.512.00
2025-06-24ARGX568.08532.0-36.412.10
2025-06-25ARGX560.77- -58.30.00
2025-06-26ARGX560.36- -55.20.00
2025-06-27ARGX559.66519.0-52.511.92
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02ARGX0.00-7.653.94
2025-06-03ARGX0.00-7.653.94
2025-06-04ARGX0.00-7.653.94
2025-06-05ARGX0.00-7.653.94
2025-06-06ARGX0.00-7.653.94
2025-06-09ARGX0.00-7.353.94
2025-06-10ARGX0.00-7.353.94
2025-06-11ARGX0.00-7.353.46
2025-06-12ARGX0.00-7.353.46
2025-06-13ARGX0.00-7.353.46
2025-06-16ARGX0.00-1.693.46
2025-06-17ARGX0.00-1.693.46
2025-06-18ARGX0.00-1.693.46
2025-06-20ARGX0.00-1.693.46
2025-06-23ARGX0.00-2.453.46
2025-06-24ARGX0.00-2.453.46
2025-06-25ARGX0.00-2.453.46
2025-06-26ARGX0.00-2.453.32
2025-06-27ARGX0.00-2.453.32
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

2.58

Avg. EPS Est. Current Quarter

2.57

Avg. EPS Est. Next Quarter

3.06

Insider Transactions

Institutional Transactions

-2.45

Beta

0.38

Average Sales Estimate Current Quarter

769

Average Sales Estimate Next Quarter

836

Fair Value

Quality Score

100

Growth Score

56

Sentiment Score

91

Actual DrawDown %

17.5

Max Drawdown 5-Year %

-38.2

Target Price

753.45

P/E

43.91

Forward P/E

26.56

PEG

1.34

P/S

15.64

P/B

6.19

P/Free Cash Flow

1264.4

EPS

12.76

Average EPS Est. Cur. Y​

11.92

EPS Next Y. (Est.)

19.72

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

38.03

Relative Volume

1.17

Return on Equity vs Sector %

-14.2

Return on Equity vs Industry %

3.6

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.15

EBIT Estimation

-52.5
argenx SE
Sector: Healthcare
Industry: Biotechnology
Employees: 1599
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
stock quote shares ARGX – argenx SE Stock Price stock today
news today ARGX – argenx SE stock forecast ,stock prediction 2023 2024 2025
marketwatch ARGX – argenx SE yahoo finance google finance
stock history ARGX – argenx SE invest stock market
stock prices ARGX premarket after hours
ticker ARGX fair value insiders trading